The scalpel that
isn’t a scalpel.

A surgical tool that fits in your hand and never touches the patient

Picture an operating room with no scalpel on the tray. A clinician holds a device about the size of a cordless drill, presses it against the skin, watches a live ultrasound image, and lines up a target somewhere inside the body. No blade goes in. Nothing is burned. A pulse of focused sound does the cutting, and the tissue it cuts is never touched by anything physical at all.

That is the room Sound Blade Medical is trying to build. The Halifax company makes a handheld histotripsy device: a way to mechanically destroy targeted tissue using focused ultrasound, guided by real-time imaging and a layer of machine-learning software. It is non-invasive, non-thermal, and non-ionizing — three negatives that, stacked together, describe something genuinely new.

The company is small — around 17 people — and pre-market. It has not sold a device. What it has is a technology, a credible team, and US$16.5 million from investors who do this for a living. For a medtech startup in 2026, that is a respectable place to be standing.

Surgery still works the way it did a century ago: you have to open the body

Modern medicine has gotten remarkably good at fixing things inside people. The catch is that, to fix them, you usually have to get inside — and getting inside means incisions, blood loss, infection risk, anesthesia, and weeks of recovery. Minimally invasive surgery shrank the incisions. It did not eliminate them.

Caption: The knife has had a very good run. Roughly 5,000 years. Sound Blade would like to schedule its retirement.

Ablation — destroying tissue in place rather than removing it — was supposed to help, and it did. But most ablation cooks tissue with heat or freezes it with cold, and both can damage whatever sits nearby. Heat also has a way of muddying the body’s own immune response to what was just destroyed.

So the question Sound Blade started with is almost embarrassingly simple: what if you could destroy exactly the tissue you wanted, leave everything around it alone, and never break the skin at all?

That sound, focused tightly enough, can do the work of steel

The answer to that question was already sitting in a lab at Dalhousie University. Jeremy Brown, a professor of biomedical engineering in Halifax, had spent years on high-frequency ultrasound. Histotripsy — using focused sound to create microscopic cavitation bubbles that mechanically tear tissue apart — was the technology. The bet was that it could be made small, handheld, and image-guided, rather than living inside a room-sized machine.

Brown co-founded the company in 2023 alongside a research-heavy bench: Matt Mallay, Andre Bezanson, Eli Vlaisavljevich, and Rick Balys, with development help from Daxsonics Ultrasound and clinical roots at Nova Scotia Health. It was, at first, a very academic kind of startup — long on physics, short on commercial scar tissue.

That changed in August 2025, when Neil Barman took over as CEO and Brown moved to Chief Technical Officer. Barman is not a first-timer: he was chief scientific officer at ReCor Medical, where he helped win FDA approval for an ultrasound renal denervation therapy, and he co-founded May Health. He has spent two decades inside medtech companies, several of which were later swallowed by Medtronic and Stryker. The founders’ bet, in other words, picked up an operator who has actually driven this kind of device through a regulator before.

How you cut something without touching it

Here is the mechanism, minus the jargon. The device sends focused ultrasound from outside the body to a precise point inside it. At that focal point, the sound is intense enough to form and collapse tiny cavitation bubbles. Those bubbles mechanically break the targeted tissue into fragments the body can clear — a process closer to liquefying than to burning. Because it is the mechanical action doing the work, there is no meaningful heat and no ionizing radiation.

Real-time imaging keeps the operator pointed at the right spot, and AI/machine-learning algorithms assist with guidance. The whole thing is designed to be handheld, which is the part that separates Sound Blade from the larger focused-ultrasound systems that came before it.

Caption: It works by making bubbles and then destroying them. Somewhere, a physicist is nodding. Somewhere else, a surgeon is asking where the off switch is.

Money is not validation. But it is a vote.

In January 2025, Sound Blade closed an oversubscribed US$16.5 million Series A — roughly C$23.8 million. The round was co-led by Amzak Health and Lumira Ventures, two firms that invest in life sciences for a living, with Invest Nova Scotia rounding it out. “Oversubscribed” is a word startups enjoy using; here it means more investors wanted in than there was room for.

The other proof point is people. Backing the science with operators who have shepherded ultrasound devices through the FDA is the kind of detail that separates a promising lab project from a company that might actually reach a patient. Partnerships with Dalhousie, Daxsonics Ultrasound, and Nova Scotia Health keep one foot in the research world while the other moves toward the clinic.

Lab roots, operator muscle

Make “going under the knife” an expression, not a procedure

Strip away the engineering and the goal is plain: better outcomes through surgery that does not require opening anyone up. Less blood. Fewer complications. Faster recovery. Lower infection risk. The mission is not to make a clever device for its own sake — it is to make a category of procedures less frightening to live through.

Caption: A company in Nova Scotia, population not large, would like to change how the rest of the planet thinks about an operation. Modest ambitions are overrated.

That said, this is medicine, and medicine is patient with no one. Sound Blade has a technology and capital, not regulatory clearance and a sales record. Histotripsy as a field is real and advancing — companies like HistoSonics have shown the FDA will engage with it — but a handheld, image-guided version still has to prove itself in trials and in front of regulators. The honest status is “promising and unproven,” which is exactly where a Series A should land.

The off switch question

Go back to that operating room with the empty tray. If Sound Blade is right, the surgeon never picks up a blade because there is nothing to pick up. The cutting happens at a focal point inside the body, the patient walks out the same day, and the most invasive thing in the room is the gel on the skin.

None of that is guaranteed. The bubbles have to behave, the imaging has to be exact, the regulators have to agree, and a 17-person company in Halifax has to do all of it before the money runs out. But the bet is clear, the science is real, and for the first time the people running it have done the regulatory part before.

Sound Blade Medical is wagering that the future of surgery is quiet, handheld, and bloodless — and that the loudest thing in the room will be the ultrasound nobody can hear.

Five facts, no filler

• Histotripsy destroys tissue with sound, not heat or blades — microscopic cavitation bubbles do the work.
• The entire pitch fits on a business card: “Histotripsy in the palm of your hand.”
• CEO Neil Barman previously helped win FDA approval for ultrasound renal denervation therapy at ReCor Medical.
• The technology started in a Dalhousie University biomedical engineering lab in Halifax, Nova Scotia.
• No incision means the potential for less blood loss, fewer complications, faster recovery, and lower infection risk than open surgery.